Quick Answer
Aprea Therapeutics, Inc. reported R&D Expense of $23.90 million for fiscal year 2021.
Aprea Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2021 | $23.90M | -36.9% |
| 2020 | $37.88M | +80.8% |
| 2019 | $20.95M | +47.6% |
| 2018 | $14.19M | +6.0% |
| 2017 | $13.39M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2022 | $4.09M | -39.5% | -32.0% |
| September 30, 2021 | $6.02M | -31.3% | -9.6% |
| June 30, 2021 | $6.65M | -37.8% | -1.6% |
| March 31, 2021 | $6.76M | -25.6% | -22.8% |
| September 30, 2020 | $8.76M | +78.4% | -18.1% |
| June 30, 2020 | $10.69M | +147.6% | +17.6% |
| March 31, 2020 | $9.10M | +147.3% | +85.2% |
| September 30, 2019 | $4.91M | +112.8% | +13.7% |
- Aprea Therapeutics, Inc. showed a decrease of -36.9% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2021 period, Aprea Therapeutics, Inc.’s r&d expense has grown by 78.4% (from $13.39 million to $23.90 million).
- The most recent figure is from Aprea Therapeutics, Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on March 15, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: